Erasca CLO Ebun Garner sells $1.3m in ERAS stock

Erasca Chief Legal Officer Ebun Garner sold 80,000 shares for $1,312,000 (prices $16.11–$16.58) and exercised options for 80,000 shares at $1.70 ($136,000 total) under a 10b5-1 plan. The company reported a net loss of $29.1M in Q4 2025 and $124.6M for FY2025, while expanding its license for ERAS-0015 to China, Hong Kong and Macau and securing worldwide rights. Stifel, H.C. Wainwright and Clear Street raised price targets to $20 and maintained constructive ratings, citing clinical progress (including two confirmed partial responses) and partnership plans (Tango Therapeutics combo testing).

Analysis

Erasca’s RAS-directed program and a planned combination with a PRMT5 agent create asymmetric clinical optionality: success expands addressable indications across multiple RAS-mutant tumors, but the combination path materially increases trial complexity (biomarker selection, dosing tolerability) and therefore the probability-weighted timeline to commercialization. Expanding China rights is a meaningful second-order lever — it accelerates patient recruitment and potential peak sales but also imposes localized commercialization costs, pricing pressure and IP enforcement risk that can compress realized margins by an order of magnitude versus western markets.

The next 6–18 months will be dominated by binary clinical and partnership catalysts; these are high-conviction, high-volatility events that can move the equity multiples 2x–3x on surprise outcomes. Countervailing risks include accelerated cash burn if broader or combo cohorts are opened, and the realistic chance of a mid-trial toxicity or biomarker miss that forces redesign — any of which would push meaningful dilution within 12–24 months. Strategically, ERAS is a plausible M&A target for a mid-to-large pharma wanting both a RAS asset and Asian rights, which caps downside in a failed independent commercialization scenario but also limits standalone upside absent clear late-stage data.

The consensus appears to underprice execution friction in China and over-weight the positive signal from early partial responses without adjusting for combo-specific safety risk. That makes the current risk/reward skewed toward binary event trading rather than a straight long-hold biotech growth bet: nimble, event-driven structures (options, call spreads, hedged equity) are preferable to concentrated outright exposure.

Key Decisions for Investors

• Initiate a tactical long ERAS position (size 1–2% NAV) with a 6–12 month horizon: fund via buying a 9–12 month call spread sized to risk no more than 1% NAV (target 150–250% payoff on positive readouts); set a hard stop to exit if interim safety flags emerge or if management signals need for dilutive financing.
• Hedge programmatic biotech risk by pairing long ERAS (1% NAV) with a short position in a biotech index ETF (IBB or XBI) sized to neutralize sector beta (~0.5% NAV short) — this isolates idiosyncratic trial upside while limiting broader market drawdown over 3–9 months.
• Event squeeze / partnership ticket: buy small-size (0.5% NAV) 12–18 month calls on TNGX to capture asymmetric upside from successful combo data or co-development headlines; downside limited to premium, upside amplified if partnership or positive combo signal emerges.
• If already long equity and seeking yield/defensive posture, sell 3–6 month covered calls to trim cost basis (target premium to offset 25–40% of near-term cash burn risk) — avoids binary premium exposure while preserving some upside participation.